Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Fireman B.V. (IFRX)

Fireman B.V. (IFRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 110,510
  • Shares Outstanding, K 44,204
  • Annual Sales, $ 0 K
  • Annual Income, $ -53,980 K
  • 60-Month Beta 1.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.05
Trade IFRX with:

Options Overview Details

View History
  • Implied Volatility 62.47% ( -4.09%)
  • Historical Volatility 75.84%
  • IV Percentile 20%
  • IV Rank 14.58%
  • IV High 421.84% on 06/17/22
  • IV Low 1.13% on 10/25/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 52
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 2,802

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.26
  • Number of Estimates 3
  • High Estimate -0.17
  • Low Estimate -0.34
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +21.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.24 +11.61%
on 11/22/22
2.77 -9.75%
on 11/11/22
-0.04 (-1.57%)
since 10/25/22
3-Month
2.08 +20.19%
on 09/23/22
2.91 -14.09%
on 09/09/22
+0.28 (+12.61%)
since 08/25/22
52-Week
0.78 +222.08%
on 06/24/22
5.57 -55.12%
on 11/26/21
-2.52 (-50.20%)
since 11/24/21

Most Recent Stories

More News
Here's Why InflaRx N.V. (IFRX) is a Great Momentum Stock to Buy

Does InflaRx N.V. (IFRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

IFRX : 2.50 (+5.04%)
InflaRx N.V. (IFRX) Upgraded to Buy: What Does It Mean for the Stock?

InflaRx N.V. (IFRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

IFRX : 2.50 (+5.04%)
InflaRx Reports Second Quarter 2022 Financial & Operating Results

Fast Track and Orphan Drug designation for vilobelimab in pyoderma gangrenosum (PG) granted by the FDAPlans to submit EUA with the FDA for vilobelimab in...

IFRX : 2.50 (+5.04%)
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients

Completed encouraging Type B meeting with US FDAApplication for EUA planned to be submitted in Q3 2022 JENA, Germany, July 26, 2022 (GLOBE NEWSWIRE) --...

IFRX : 2.50 (+5.04%)
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

US Food and Drug Administration awards Fast Track designation for the treatment of ulcerative pyoderma gangrenosumFast track follows recently reported...

IFRX : 2.50 (+5.04%)
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMAProductive end-of-phase II meeting with FDA held for PG;...

IFRX : 2.50 (+5.04%)
InflaRx to Present at the H.C. Wainwright Global Investment Conference

JENA, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory...

IFRX : 2.50 (+5.04%)
InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update

Quarter highlighted by progress with vilobelimab in several indications: Encouraging Phase III topline results reported in patients with severe...

IFRX : 2.50 (+5.04%)
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients

Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show...

IFRX : 2.50 (+5.04%)
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates

InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 10.81% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

IFRX : 2.50 (+5.04%)
SRNE : 1.3500 (-2.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany.

See More

Key Turning Points

3rd Resistance Point 2.74
2nd Resistance Point 2.62
1st Resistance Point 2.56
Last Price 2.50
1st Support Level 2.38
2nd Support Level 2.26
3rd Support Level 2.20

See More

52-Week High 5.57
Fibonacci 61.8% 3.74
Fibonacci 50% 3.17
Fibonacci 38.2% 2.61
Last Price 2.50
52-Week Low 0.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar